Loading…
Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil
Objective: Brain drug delivery for effective treatment of neurodegenerative disorders is limited due to the selective permeability of blood brain barrier (BBB). During the past few years, development of novel delivery system has attracted considerable attention of formulation scientists to overcome...
Saved in:
| Published in: | Drug development and industrial pharmacy 2020-01, Vol.46 (1), p.8-19 |
|---|---|
| Main Authors: | , , , , , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c366t-c844fd96891b1937472251c647c10edf53cf7b36e23a8a11b2ca1d4f6e0c29d63 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c366t-c844fd96891b1937472251c647c10edf53cf7b36e23a8a11b2ca1d4f6e0c29d63 |
| container_end_page | 19 |
| container_issue | 1 |
| container_start_page | 8 |
| container_title | Drug development and industrial pharmacy |
| container_volume | 46 |
| creator | Singh, Anurag Kumar Mishra, Sunil Kumar Mishra, Gaurav Maurya, Anand Awasthi, Rajendra Yadav, Mukesh Kumar Atri, Neelam Pandey, Pawan Kumar Singh, Santosh Kumar |
| description | Objective: Brain drug delivery for effective treatment of neurodegenerative disorders is limited due to the selective permeability of blood brain barrier (BBB). During the past few years, development of novel delivery system has attracted considerable attention of formulation scientists to overcome the permeability limitation caused by BBB.
Significance: Based on the outcomes of this study and taking into consideration of the unique characteristics of laponite, it can be further explored to deliver many other central nervous system acting drugs.
Methods: In the present study, laponite (LAP) nanocomposites were exploited for the improved brain delivery of donepezil (DZ) following encapsulation approach due to their nano-size and positive charge at pH |
| doi_str_mv | 10.1080/03639045.2019.1698594 |
| format | article |
| fullrecord | <record><control><sourceid>pubmed_infor</sourceid><recordid>TN_cdi_pubmed_primary_31809608</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>31809608</sourcerecordid><originalsourceid>FETCH-LOGICAL-c366t-c844fd96891b1937472251c647c10edf53cf7b36e23a8a11b2ca1d4f6e0c29d63</originalsourceid><addsrcrecordid>eNp9kMtKxDAUQIMoOo5-gpIf6JhHkzY7RXyB4EbX5TYPJ9omJalK_Xo7zOjS1V3cc-6Fg9AZJStKanJBuOSKlGLFCFUrKlUtVLmHFlQwUohKsn202DDFBjpCxzm_EUKZEuIQHXFaEyVJvUDpIcT0CsFrrDuYcIAQdeyHmP1ocZ7yaHvsYsK-H1L8tAbrdex8sPMiQbbYh7Vv_ehjwBAMbhP4gIc1pB50fJ_B0euMo8MmBjvYb9-doAMHXbanu7lEL7c3z9f3xePT3cP11WOhuZRjoeuydEbJWtGWKl6VFWOCallWmhJrnODaVS2XlnGogdKWaaCmdNISzZSRfInE9q5OMedkXTMk30OaGkqaTcPmt2GzadjsGs7e-dYbPtremj_rN9oMXG4BH-YyPXzF1JlmhKmLySUI2ucZ_vfHD6kvg9s</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil</title><source>EBSCOhost Business Source Ultimate</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Singh, Anurag Kumar ; Mishra, Sunil Kumar ; Mishra, Gaurav ; Maurya, Anand ; Awasthi, Rajendra ; Yadav, Mukesh Kumar ; Atri, Neelam ; Pandey, Pawan Kumar ; Singh, Santosh Kumar</creator><creatorcontrib>Singh, Anurag Kumar ; Mishra, Sunil Kumar ; Mishra, Gaurav ; Maurya, Anand ; Awasthi, Rajendra ; Yadav, Mukesh Kumar ; Atri, Neelam ; Pandey, Pawan Kumar ; Singh, Santosh Kumar</creatorcontrib><description>Objective: Brain drug delivery for effective treatment of neurodegenerative disorders is limited due to the selective permeability of blood brain barrier (BBB). During the past few years, development of novel delivery system has attracted considerable attention of formulation scientists to overcome the permeability limitation caused by BBB.
Significance: Based on the outcomes of this study and taking into consideration of the unique characteristics of laponite, it can be further explored to deliver many other central nervous system acting drugs.
Methods: In the present study, laponite (LAP) nanocomposites were exploited for the improved brain delivery of donepezil (DZ) following encapsulation approach due to their nano-size and positive charge at pH <9.
Result: The size of prepared nanocomposites was 53.7 ± 4.0 to 137.7 ± 11.0 nm. The drug was released in a sustained manner till 120 h in phosphate buffer saline (pH 7.4) and acid phthalate buffer (pH 4.0). LAPDZ formulations inhibited acetylcholinesterase approximately by 82%, significantly higher (p < 0.05) than plain DZ (30%). Swiss albino mice exhibited enhanced brain uptake of LAPDZ administered via intravenous route. Promising pharmacokinetic parameters were observed in animals treated with LAPDZ. LAPDZ formulation showed half-life (t
1/2
), volume of distribution (Vd) and clearance (Cl) as 5.53 ± 0.40 h
−1
, 0.129 ± 0.02 L, 0.015 ± 0.002 L/h, respectively. While DZ solution showed the same parameters as 1.06 ± 0.12 h
−1
, 0.168 ± 0.01 L, 0.106 ± 0.013 L/h, respectively. The brain uptake of LAPDZ formulation was improved with quintuplet t
1/2
.
Conclusion: Based on the results of present study, it is proposed that the formulated nanocomposite would result in improved patient compliance with therapeutic effect at lower doses.</description><identifier>ISSN: 0363-9045</identifier><identifier>EISSN: 1520-5762</identifier><identifier>DOI: 10.1080/03639045.2019.1698594</identifier><identifier>PMID: 31809608</identifier><language>eng</language><publisher>England: Taylor & Francis</publisher><subject>Alzheimer's disease ; blood brain barrier ; brain delivery ; laponite ; nanocomposite ; nanotechnology ; neurodegenerative disorders</subject><ispartof>Drug development and industrial pharmacy, 2020-01, Vol.46 (1), p.8-19</ispartof><rights>2019 Informa UK Limited, trading as Taylor & Francis Group 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c366t-c844fd96891b1937472251c647c10edf53cf7b36e23a8a11b2ca1d4f6e0c29d63</citedby><cites>FETCH-LOGICAL-c366t-c844fd96891b1937472251c647c10edf53cf7b36e23a8a11b2ca1d4f6e0c29d63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31809608$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singh, Anurag Kumar</creatorcontrib><creatorcontrib>Mishra, Sunil Kumar</creatorcontrib><creatorcontrib>Mishra, Gaurav</creatorcontrib><creatorcontrib>Maurya, Anand</creatorcontrib><creatorcontrib>Awasthi, Rajendra</creatorcontrib><creatorcontrib>Yadav, Mukesh Kumar</creatorcontrib><creatorcontrib>Atri, Neelam</creatorcontrib><creatorcontrib>Pandey, Pawan Kumar</creatorcontrib><creatorcontrib>Singh, Santosh Kumar</creatorcontrib><title>Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil</title><title>Drug development and industrial pharmacy</title><addtitle>Drug Dev Ind Pharm</addtitle><description>Objective: Brain drug delivery for effective treatment of neurodegenerative disorders is limited due to the selective permeability of blood brain barrier (BBB). During the past few years, development of novel delivery system has attracted considerable attention of formulation scientists to overcome the permeability limitation caused by BBB.
Significance: Based on the outcomes of this study and taking into consideration of the unique characteristics of laponite, it can be further explored to deliver many other central nervous system acting drugs.
Methods: In the present study, laponite (LAP) nanocomposites were exploited for the improved brain delivery of donepezil (DZ) following encapsulation approach due to their nano-size and positive charge at pH <9.
Result: The size of prepared nanocomposites was 53.7 ± 4.0 to 137.7 ± 11.0 nm. The drug was released in a sustained manner till 120 h in phosphate buffer saline (pH 7.4) and acid phthalate buffer (pH 4.0). LAPDZ formulations inhibited acetylcholinesterase approximately by 82%, significantly higher (p < 0.05) than plain DZ (30%). Swiss albino mice exhibited enhanced brain uptake of LAPDZ administered via intravenous route. Promising pharmacokinetic parameters were observed in animals treated with LAPDZ. LAPDZ formulation showed half-life (t
1/2
), volume of distribution (Vd) and clearance (Cl) as 5.53 ± 0.40 h
−1
, 0.129 ± 0.02 L, 0.015 ± 0.002 L/h, respectively. While DZ solution showed the same parameters as 1.06 ± 0.12 h
−1
, 0.168 ± 0.01 L, 0.106 ± 0.013 L/h, respectively. The brain uptake of LAPDZ formulation was improved with quintuplet t
1/2
.
Conclusion: Based on the results of present study, it is proposed that the formulated nanocomposite would result in improved patient compliance with therapeutic effect at lower doses.</description><subject>Alzheimer's disease</subject><subject>blood brain barrier</subject><subject>brain delivery</subject><subject>laponite</subject><subject>nanocomposite</subject><subject>nanotechnology</subject><subject>neurodegenerative disorders</subject><issn>0363-9045</issn><issn>1520-5762</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kMtKxDAUQIMoOo5-gpIf6JhHkzY7RXyB4EbX5TYPJ9omJalK_Xo7zOjS1V3cc-6Fg9AZJStKanJBuOSKlGLFCFUrKlUtVLmHFlQwUohKsn202DDFBjpCxzm_EUKZEuIQHXFaEyVJvUDpIcT0CsFrrDuYcIAQdeyHmP1ocZ7yaHvsYsK-H1L8tAbrdex8sPMiQbbYh7Vv_ehjwBAMbhP4gIc1pB50fJ_B0euMo8MmBjvYb9-doAMHXbanu7lEL7c3z9f3xePT3cP11WOhuZRjoeuydEbJWtGWKl6VFWOCallWmhJrnODaVS2XlnGogdKWaaCmdNISzZSRfInE9q5OMedkXTMk30OaGkqaTcPmt2GzadjsGs7e-dYbPtremj_rN9oMXG4BH-YyPXzF1JlmhKmLySUI2ucZ_vfHD6kvg9s</recordid><startdate>20200102</startdate><enddate>20200102</enddate><creator>Singh, Anurag Kumar</creator><creator>Mishra, Sunil Kumar</creator><creator>Mishra, Gaurav</creator><creator>Maurya, Anand</creator><creator>Awasthi, Rajendra</creator><creator>Yadav, Mukesh Kumar</creator><creator>Atri, Neelam</creator><creator>Pandey, Pawan Kumar</creator><creator>Singh, Santosh Kumar</creator><general>Taylor & Francis</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>20200102</creationdate><title>Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil</title><author>Singh, Anurag Kumar ; Mishra, Sunil Kumar ; Mishra, Gaurav ; Maurya, Anand ; Awasthi, Rajendra ; Yadav, Mukesh Kumar ; Atri, Neelam ; Pandey, Pawan Kumar ; Singh, Santosh Kumar</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c366t-c844fd96891b1937472251c647c10edf53cf7b36e23a8a11b2ca1d4f6e0c29d63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Alzheimer's disease</topic><topic>blood brain barrier</topic><topic>brain delivery</topic><topic>laponite</topic><topic>nanocomposite</topic><topic>nanotechnology</topic><topic>neurodegenerative disorders</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singh, Anurag Kumar</creatorcontrib><creatorcontrib>Mishra, Sunil Kumar</creatorcontrib><creatorcontrib>Mishra, Gaurav</creatorcontrib><creatorcontrib>Maurya, Anand</creatorcontrib><creatorcontrib>Awasthi, Rajendra</creatorcontrib><creatorcontrib>Yadav, Mukesh Kumar</creatorcontrib><creatorcontrib>Atri, Neelam</creatorcontrib><creatorcontrib>Pandey, Pawan Kumar</creatorcontrib><creatorcontrib>Singh, Santosh Kumar</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Drug development and industrial pharmacy</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singh, Anurag Kumar</au><au>Mishra, Sunil Kumar</au><au>Mishra, Gaurav</au><au>Maurya, Anand</au><au>Awasthi, Rajendra</au><au>Yadav, Mukesh Kumar</au><au>Atri, Neelam</au><au>Pandey, Pawan Kumar</au><au>Singh, Santosh Kumar</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil</atitle><jtitle>Drug development and industrial pharmacy</jtitle><addtitle>Drug Dev Ind Pharm</addtitle><date>2020-01-02</date><risdate>2020</risdate><volume>46</volume><issue>1</issue><spage>8</spage><epage>19</epage><pages>8-19</pages><issn>0363-9045</issn><eissn>1520-5762</eissn><abstract>Objective: Brain drug delivery for effective treatment of neurodegenerative disorders is limited due to the selective permeability of blood brain barrier (BBB). During the past few years, development of novel delivery system has attracted considerable attention of formulation scientists to overcome the permeability limitation caused by BBB.
Significance: Based on the outcomes of this study and taking into consideration of the unique characteristics of laponite, it can be further explored to deliver many other central nervous system acting drugs.
Methods: In the present study, laponite (LAP) nanocomposites were exploited for the improved brain delivery of donepezil (DZ) following encapsulation approach due to their nano-size and positive charge at pH <9.
Result: The size of prepared nanocomposites was 53.7 ± 4.0 to 137.7 ± 11.0 nm. The drug was released in a sustained manner till 120 h in phosphate buffer saline (pH 7.4) and acid phthalate buffer (pH 4.0). LAPDZ formulations inhibited acetylcholinesterase approximately by 82%, significantly higher (p < 0.05) than plain DZ (30%). Swiss albino mice exhibited enhanced brain uptake of LAPDZ administered via intravenous route. Promising pharmacokinetic parameters were observed in animals treated with LAPDZ. LAPDZ formulation showed half-life (t
1/2
), volume of distribution (Vd) and clearance (Cl) as 5.53 ± 0.40 h
−1
, 0.129 ± 0.02 L, 0.015 ± 0.002 L/h, respectively. While DZ solution showed the same parameters as 1.06 ± 0.12 h
−1
, 0.168 ± 0.01 L, 0.106 ± 0.013 L/h, respectively. The brain uptake of LAPDZ formulation was improved with quintuplet t
1/2
.
Conclusion: Based on the results of present study, it is proposed that the formulated nanocomposite would result in improved patient compliance with therapeutic effect at lower doses.</abstract><cop>England</cop><pub>Taylor & Francis</pub><pmid>31809608</pmid><doi>10.1080/03639045.2019.1698594</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-9045 |
| ispartof | Drug development and industrial pharmacy, 2020-01, Vol.46 (1), p.8-19 |
| issn | 0363-9045 1520-5762 |
| language | eng |
| recordid | cdi_pubmed_primary_31809608 |
| source | EBSCOhost Business Source Ultimate; Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
| subjects | Alzheimer's disease blood brain barrier brain delivery laponite nanocomposite nanotechnology neurodegenerative disorders |
| title | Inorganic clay nanocomposite system for improved cholinesterase inhibition and brain pharmacokinetics of donepezil |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T14%3A16%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Inorganic%20clay%20nanocomposite%20system%20for%20improved%20cholinesterase%20inhibition%20and%20brain%20pharmacokinetics%20of%20donepezil&rft.jtitle=Drug%20development%20and%20industrial%20pharmacy&rft.au=Singh,%20Anurag%20Kumar&rft.date=2020-01-02&rft.volume=46&rft.issue=1&rft.spage=8&rft.epage=19&rft.pages=8-19&rft.issn=0363-9045&rft.eissn=1520-5762&rft_id=info:doi/10.1080/03639045.2019.1698594&rft_dat=%3Cpubmed_infor%3E31809608%3C/pubmed_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c366t-c844fd96891b1937472251c647c10edf53cf7b36e23a8a11b2ca1d4f6e0c29d63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/31809608&rfr_iscdi=true |